Pharma Mar Continues Share Buyback With February Purchases on Madrid Exchange

Pharma Mar SA ( (ES:PHM) ) just unveiled an update.

Pharma Mar SA has continued its previously announced share buyback programme, disclosing purchases of its own shares on the Madrid Stock Exchange between 1 and 28 February 2026 at average prices generally ranging from about €75 to €79 per share. The transactions, executed through JB Capital Markets as intermediary, form part of the company’s ongoing capital management strategy, potentially supporting the stock price and signaling management’s confidence in the business to investors.

The latest tranche of repurchases adds to the buyback that began in October 2025 and indicates a sustained commitment to returning value to shareholders through reductions in free float or treasury stock usage for corporate purposes. For stakeholders, the continued pace and pricing of these acquisitions provide insight into how Pharma Mar is allocating cash and how it views its current market valuation relative to its long-term prospects.

The most recent analyst rating on (ES:PHM) stock is a Buy with a EUR120.00 price target. To see the full list of analyst forecasts on Pharma Mar SA stock, see the ES:PHM Stock Forecast page.

More about Pharma Mar SA

Pharma Mar SA is a Spain-based biopharmaceutical company focused on the research, development and commercialization of oncology medicines, particularly marine-derived anticancer drugs. The company is listed on the Spanish stock exchange and targets global cancer treatment markets through both proprietary products and licensing partnerships.

Average Trading Volume: 33,720

Technical Sentiment Signal: Strong Buy

Current Market Cap: €1.49B

Find detailed analytics on PHM stock on TipRanks’ Stock Analysis page.